Nicholas Conrad Smith sold $3.6M of ANRO
PRESIDENT AND CFO at Alto Neuroscience, Inc.. 134,886 shares at an average of $26.45, traded Sep 29, 2026, filed Oct 1, 2026.
Score components
- +22RoleCFO
- +25Trade size$3.6M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002009130-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | MOption exercise Common Stock10b5-1 | +56,455 | $2.35 | $133k | 80,515 | 13 d ago |
| Sep 29, 2026 | MOption exercise Common Stock10b5-1 | +54,375 | $2.35 | $128k | 134,890 | 13 d ago |
| Sep 29, 2026 | SOpen-market sale Common Stock10b5-1 | -110,830 | $26.58 | $2.9M | 24,060 | 13 d ago |
| Sep 30, 2026 | MOption exercise Common Stock10b5-1 | +24,056 | $2.35 | $57k | 48,116 | 13 d ago |
| Sep 30, 2026 | SOpen-market sale Common Stock10b5-1 | -23,170 | $25.78 | $597k | 24,946 | 13 d ago |
| Sep 30, 2026 | SOpen-market sale Common Stock10b5-1 | -886 | $26.87 | $24k | 24,060 | 13 d ago |
| Sep 29, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -56,455 | $0.00 | $0 | 145,874 | 13 d ago |
| Sep 29, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -54,375 | $0.00 | $0 | 35,625 | 13 d ago |
| Sep 30, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -24,056 | $0.00 | $0 | 121,818 | 13 d ago |
Related signals
Other insiders at Alto Neuroscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | ANRObuy Alto Neuroscience, Inc. | Adam Savitz CHIEF MEDICAL OFFICER | $191k 15,000 shares | +60% | |
| 47Moderate | ANRObuy Alto Neuroscience, Inc. | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | $101k 6,150 shares | +30% | |
| 60Notable | Alto Neuroscience, Inc. | Alpha Wave Global, LP owner | $9.6M 600,000 shares | +19% | |
| 52Moderate | Alto Neuroscience, Inc. | Amit Etkin PRESIDENT AND CEO | $50k 3,125 shares | +0% | |
| 63Notable | Alto Neuroscience, Inc. | Adam Savitz CHIEF MEDICAL OFFICER | $272k 17,000 shares | +217% | |
| 60Notable | Alto Neuroscience, Inc. | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | $25k 1,563 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.